๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Tenecteplase

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 10 trials in our China and India registers that name Tenecteplase as an intervention. Synced 24 Sep 2026
10Trials tracked
7Recruiting now
7Lead sponsors
2Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Tenecteplase is named as a drug or biological intervention in 10 clinical trials in our China and India trial registers, 7 of which are recruiting. Lead sponsors include Beijing Tiantan Hospital (3), General Hospital of Shenyang Military Region (2) and Boehringer Ingelheim (1). Registered phases: Phase 3, Observational and Phase 2. Conditions studied include Stroke; Acute Ischemic Stroke; Ischemic Stroke.

01

Clinical trials of Tenecteplase

10 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06658197 Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke (ClinicalTrials.gov ↗)
Stroke, Ischemic, Stroke, Acute, Thrombosis, Brain
Phase 3 Recruiting Xuanwu Hospital, Beijing China
NCT06954155 Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND (ClinicalTrials.gov ↗)
Stroke
Phase 3 Recruiting Beijing Tiantan Hospital China
NCT07047014 Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke (ClinicalTrials.gov ↗)
Stroke, Ischemic, Medium Vessel Occlusions
Phase 3 Recruiting Beijing Tiantan Hospital China
NCT07361302 A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
Acute Ischemic Stroke
Phase 3 Recruiting Boehringer Ingelheim India, China
NCT07375953 Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) (ClinicalTrials.gov ↗)
Ischemic Stroke
Phase 2 Recruiting General Hospital of Shenyang Military Region China
NCT07375966 Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2) (ClinicalTrials.gov ↗)
Ischemic Stroke
Phase 2 Recruiting General Hospital of Shenyang Military Region China
NCT07271342 Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China (ClinicalTrials.gov ↗)
Stroke
Observational Recruiting Beijing Tiantan Hospital China
NCT07471282 Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy (ClinicalTrials.gov ↗)
Stroke
Phase 3 Not yet open Chuansheng Zhao China
NCT07476898 Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (ClinicalTrials.gov ↗)
Stroke
Phase 3 Not yet open First Hospital of China Medical University China
NCT07536165 Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke (ClinicalTrials.gov ↗)
Stroke, Acute Ischemic Stroke
Observational Not yet open Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

8 conditions
Condition (as registered)Trials
Stroke5
Acute Ischemic Stroke2
Ischemic Stroke2
Stroke, Ischemic2
Medium Vessel Occlusions1
Stroke, Acute1
Thrombosis, Brain1
Drug Effect1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Beijing Tiantan Hospital3
General Hospital of Shenyang Military Region2
Boehringer Ingelheim1
Chuansheng Zhao1
Xuanwu Hospital, Beijing1
First Hospital of China Medical University1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
04

Trials by country register

RegisterTenecteplase trials
Clinical trials in China10
Clinical trials in India1

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Tenecteplase works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tenecteplase (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.